ONCT: oncternal.com Amount of Cash per Share

Corporate emblem and logo of Oncternal Therapeutics (ONCT)

Oncternal Therapeutics (ONCT) is currently preserving capital and exploring merger options due to the suspension of its programs. This GURU.Markets chart of cash per share visualizes this process, where 4.93 reflects the current value of the metric. The company focuses on rare lymphoma therapies, fully outsourcing synthesis and testing to external vendors.

ONCT: Oncternal Therapeutics Inc Cash per Share 07/04/2022 - 12/14/2024

Analytical breakdowns for Oncternal Therapeutics

- market price and analyst price targets:
- cash position and cash flow details:
Summary company analysis:ONCT, Oncternal Corp
Original product of oncternal.com

Assessing the reliability of equity assets begins with an analysis of the liquid reserve per common share. This metric determines the volume of available cash distributed across all issued securities. For Oncternal Therapeutics (ONCT), this reserve is critical for maintaining compliance with strict FDA regulations in the biopharmaceutical sector. The cash-per-share trend reflects the company's ability to fund clinical trials. Analyzing cash per share allows for the identification of risks associated with inefficient capital management.